WO2000015175A3 - Use as an active substance of molecules binding to beta-1-integrin with the capacity to kill cells - Google Patents

Use as an active substance of molecules binding to beta-1-integrin with the capacity to kill cells Download PDF

Info

Publication number
WO2000015175A3
WO2000015175A3 PCT/SE1999/001560 SE9901560W WO0015175A3 WO 2000015175 A3 WO2000015175 A3 WO 2000015175A3 SE 9901560 W SE9901560 W SE 9901560W WO 0015175 A3 WO0015175 A3 WO 0015175A3
Authority
WO
WIPO (PCT)
Prior art keywords
capacity
integrins
kill cells
active substance
integrin
Prior art date
Application number
PCT/SE1999/001560
Other languages
French (fr)
Other versions
WO2000015175A2 (en
Inventor
Ignacio Arencibia
Karl-Goesta Sundqvist
Original Assignee
Ignacio Arencibia
Sundqvist Karl Goesta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9803098A external-priority patent/SE9803098D0/en
Application filed by Ignacio Arencibia, Sundqvist Karl Goesta filed Critical Ignacio Arencibia
Priority to AU62357/99A priority Critical patent/AU6235799A/en
Priority to EP99949501A priority patent/EP1112078A2/en
Priority to JP2000569760A priority patent/JP2003527307A/en
Publication of WO2000015175A2 publication Critical patent/WO2000015175A2/en
Publication of WO2000015175A3 publication Critical patent/WO2000015175A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

The present invention relates to the use as an active substance of molecules binding to β1-integrins and with the capacity to kill cells having β1-integrins for production of pharmaceuticals for treatment of conditions dependent on cells having β1-integrins such as cancer and conditions dependent on T lymphocytes and fibrotic conditions. Especially the invention relates to the use of Invasin (Inv) from Yersinia (Yer) species, subfragments, variants, and peptides thereof, microorganisms producing invasin and invasin like substances and antibodies binding β1-integrins and with the capacity to kill cells having β1-integrins.
PCT/SE1999/001560 1998-09-10 1999-09-08 Use as an active substance of molecules binding to beta-1-integrin with the capacity to kill cells WO2000015175A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU62357/99A AU6235799A (en) 1998-09-10 1999-09-08 New use
EP99949501A EP1112078A2 (en) 1998-09-10 1999-09-08 New use
JP2000569760A JP2003527307A (en) 1998-09-10 1999-09-08 New use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9803098-4 1998-09-10
SE9803098A SE9803098D0 (en) 1998-09-10 1998-09-10 new use
US13579899P 1999-05-24 1999-05-24
US60/135,798 1999-05-24

Publications (2)

Publication Number Publication Date
WO2000015175A2 WO2000015175A2 (en) 2000-03-23
WO2000015175A3 true WO2000015175A3 (en) 2000-07-13

Family

ID=26663397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1999/001560 WO2000015175A2 (en) 1998-09-10 1999-09-08 Use as an active substance of molecules binding to beta-1-integrin with the capacity to kill cells

Country Status (4)

Country Link
EP (1) EP1112078A2 (en)
JP (1) JP2003527307A (en)
AU (1) AU6235799A (en)
WO (1) WO2000015175A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3412686A1 (en) 2003-10-17 2018-12-12 AlJamal-Naylor, Rehab Tissue repair by modulation of beta-1 integrin biological function
US20060217308A1 (en) * 2005-03-10 2006-09-28 Pascale Cossart Compositions for the treatment of tumor pathologies, comprising internalin B (ln1B) of Listeria monocytogene protein or a fragment thereof
JP2007008895A (en) * 2005-07-04 2007-01-18 Chugai Pharmaceut Co Ltd Combined use of anti-cd47 antibody and integrin ligand
GB0703652D0 (en) 2007-02-26 2007-04-04 Univ Bradford Method for the allosteric modulation of beta1 integrin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013250A1 (en) * 1994-10-27 1996-05-09 Amgem Inc. Compositions for increased bioavailability of orally delivered therapeutic agents
US5846536A (en) * 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013250A1 (en) * 1994-10-27 1996-05-09 Amgem Inc. Compositions for increased bioavailability of orally delivered therapeutic agents
US5846536A (en) * 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE, [online] MITRA R.S. ET AL.: "Apoptosis in keratinocytes is not dependent on induction of differentiation", XP002944349, accession no. Dialog Database accession no. 9010453 *
LAB. INVEST., vol. 76, no. 1, January 1997 (1997-01-01), pages 99 - 107 *
NANCY BOUDREAU ET AL.: "Suppression of ICE and Apoptosis in Mammary Epithelial Cells by Extracellular Matrix", SCIENCE,, vol. 267, 10 February 1995 (1995-02-10), pages 891 - 893, XP002925810 *

Also Published As

Publication number Publication date
WO2000015175A2 (en) 2000-03-23
AU6235799A (en) 2000-04-03
EP1112078A2 (en) 2001-07-04
JP2003527307A (en) 2003-09-16

Similar Documents

Publication Publication Date Title
ID30111A (en) SHEETS THAT CAN BE OBTAINED LIQUID FOR THE BODY ABSORPTION ABSORPTION MATERIAL, APARATUS AND THE PRODUCTION METHOD (Fraction from NO. P970605)
MA26508A1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING VARICONAZOLE, AND PROCESS FOR THEIR PREPARATION.
EA200200105A1 (en) Compounds modulating PPARγ activity;
WO1998051712A1 (en) Chitin beads, chitosan beads, processes for producing these beads, carriers made of these beads and processes for producing microsprodidian spores
CA2362251A1 (en) Methods for preserving dna integrity
AU5210798A (en) Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use
CA2276747A1 (en) Methods and devices for the reduction of small organic compounds from blood products
AU2374100A (en) Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and use
WO2000015175A3 (en) Use as an active substance of molecules binding to beta-1-integrin with the capacity to kill cells
AU5143099A (en) Protein fragment complementation assays for the detection of biological or drug interactions
AU4943496A (en) Process and compounds for detection of analytes using remanence measurement, and use thereof
AU7987398A (en) One step device and process for concentration and purification of biological molecules
WO1999039009A8 (en) Processes for isolating, amplifying and characterizing dna
AU5634099A (en) Composition for the removal of biological and organic substances
AU3258097A (en) Pharmaceutical composition containing an embryonic or gravid uterus extract as an active substance and relative preparation process
AU7595298A (en) Azolidinediones useful for the treatment of diabetes, dyslipidemia and hy pertension
AU4779599A (en) Methods of inhibiting (helicobacter pylori)
ZA987412B (en) 3-Arylsuccinamidohydroxamic acids, processes for their preparation, and drugs containing these substances.
FR2755438B1 (en) COMPOUND, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
AU5186396A (en) Hematophagous insect calreticulin nucleic acid molecules, proteins and uses thereof
WO1998022508A3 (en) Process for tumour cell depletion of cd34-positive cells
FR2777751B1 (en) PROTEIN SUPPLEMENT, FOOD COMPOSITION CONTAINING THE SAME, PROCESS FOR THEIR PREPARATION AND THEIR USE.
FR2741087B1 (en) ADENOVIRAL DODECAEDRIC PROTEIN COMPLEX, PREPARATION METHOD, COMPOSITION CONTAINING THE SAME AND ITS APPLICATIONS
AU2151697A (en) Increased yields of a crystallized protein by using a solid adsorption material
WO2002055550A3 (en) Crystallization and structure determination of fema and/or fema-like proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 569760

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999949501

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09786770

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999949501

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999949501

Country of ref document: EP